{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:20:28Z","timestamp":1783682428513,"version":"3.55.0"},"reference-count":54,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,5,24]]},"DOI":"10.1248\/bpb.b25-00057","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T22:08:35Z","timestamp":1748038115000},"page":"694-705","source":"Crossref","is-referenced-by-count":4,"title":["Prospective Analysis of Factors Influencing Inter-Individual Variation in Trough Plasma Voriconazole Concentrations in Older Patients\u2014Impact of High <i>\u03b1<\/i>1-Acid Glycoprotein Levels"],"prefix":"10.1248","volume":"48","author":[{"given":"Yukako","family":"Yasui","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Sakai City Medical Centre, 1\u20131\u20131 Ebaraji-cho, Nishi-ku, Sakai 593\u20138304, Japan"},{"name":"Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yasui","sequence":"additional","affiliation":[{"name":"Department of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Chemistry, Kyoto Pharmaceutical University, 5 Nakauchi-cho, Misasagi, Yamashina-ku, Kyoto 607\u20138414, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sakai City Medical Centre, 1\u20131\u20131 Ebaraji-cho, Nishi-ku, Sakai 593\u20138304, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Ishizaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Sakai City Medical Centre, 1\u20131\u20131 Ebaraji-cho, Nishi-ku, Sakai 593\u20138304, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sakai City Medical Centre, 1\u20131\u20131 Ebaraji-cho, Nishi-ku, Sakai 593-8304, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waki","family":"Imoto","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"},{"name":"Department of Infection Control, Osaka Metropolitan University Hospital, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"},{"name":"Department of Infection Control, Osaka Metropolitan University Hospital, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"},{"name":"Department of Infection Control, Osaka Metropolitan University Hospital, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kakeya","sequence":"additional","affiliation":[{"name":"Department of Infection Control Science, Osaka Metropolitan University Graduate School of Medicine, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"},{"name":"Department of Infection Control, Osaka Metropolitan University Hospital, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"},{"name":"Research Centre for Infectious Disease Science (RCIDS), Osaka Metropolitan University Graduate School of Medicine, 1\u20134\u20133 Asahi-machi, Abeno-ku, Osaka 545\u20138585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ueda K, Nannya Y, Kumano K, Hangaishi A, Takahashi T, Imai Y, Kurokawa M. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int. J. Hematol.<\/i>, 89<\/b>, 592\u2013599 (2009).","DOI":"10.1007\/s12185-009-0296-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.<\/i>, 46<\/b>, 201\u2013211 (2008).","DOI":"10.1086\/524669"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hamada Y, Seto Y, Yago K, Kuroyama M. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. J. Infect. Chemother.<\/i>, 18<\/b>, 501\u2013507 (2012).","DOI":"10.1007\/s10156-011-0363-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Matsumoto K, Abematsu K, Shigemi A, Kanazawa N, Watanabe E, Yokoyama Y, Ikawa K, Morikawa N, Takeda Y. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data. J. Chemother.<\/i>, 28<\/b>, 198\u2013202 (2016).","DOI":"10.1179\/1973947815Y.0000000057"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol.<\/i>, 56<\/b>(Suppl. 1), 10\u201316 (2003).","DOI":"10.1046\/j.1365-2125.2003.01993.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2Cl9 genotypes. Int. J. Antimicrob. Agents<\/i>, 34<\/b>, 91\u201394 (2009).","DOI":"10.1016\/j.ijantimicag.2009.01.008"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kakuda TN, Van Solingen-Ristea R, Aharchi F, De Smedt G, Witek J, Nijs S, Vyncke V, Richard MW, Hoetelmans RMW. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers. J. Clin. Pharmacol.<\/i>, 53<\/b>, 41\u201350 (2013).","DOI":"10.1177\/0091270011433329"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Li X, Yu C, Wang T, Chen K, Zhai S, Tang H. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. Eur. J. Clin. Pharmacol.<\/i>, 72<\/b>, 1185\u20131193 (2016).","DOI":"10.1007\/s00228-016-2089-y"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Mikus G, Sch\u00f6wel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD, Burhenne J, Weiss J, Thomsen T, Haefeli WE. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin. Pharmacol. Ther.<\/i>, 80<\/b>, 126\u2013135 (2006).","DOI":"10.1016\/j.clpt.2006.04.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Kubota T, Chiba K, Ishizaki T. Genotyping of S<\/i>-mephenytoin 4\u2032-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther.<\/i>, 60<\/b>, 661\u2013666 (1996).","DOI":"10.1016\/S0009-9236(96)90214-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Umemura T, Kakizaki H, Mutoh Y, Mizuno T, Ito Y, Hioki T, Kato H, Hagihara M, Yamada T, Ikeda Y, Mikamo H, Ichihara T, Hamada Y. Effectiveness and safety of the simulation-based first-dose design of voriconazole. J. Infect. Chemother.<\/i>, 31<\/b>, 102453 (2025).","DOI":"10.1016\/j.jiac.2024.06.016"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Chantharit P, Tantasawat M, Kasai H, Tanigawara Y. Population pharmacokinetics of voriconazole in patients with invasive aspergillosis: serum albumin level as a novel marker for clearance and dosage optimization. Ther. Drug Monit.<\/i>, 42<\/b>, 872\u2013879 (2020).","DOI":"10.1097\/FTD.0000000000000799"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Wang T, Yan M, Tang D, Xue L, Zhang T, Dong Y, Zhu L, Wang X, Dong Y. A Retrospective, multicentre study of voriconazole trough concentrations and safety in patients with Child\u2013Pugh class C cirrhosis. J. Clin. Pharm. Ther.<\/i>, 43<\/b>, 849\u2013854 (2018).","DOI":"10.1111\/jcpt.12724"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nashimoto S, Imai S, Sugawara M, Takekuma Y. Usefulness of the albumin-bilirubin score in determining the initial dose of voriconazole for patients with liver cirrhosis. Biol. Pharm. Bull.<\/i>, 46<\/b>, 230\u2013236 (2023).","DOI":"10.1248\/bpb.b22-00608"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Vreugdenhil B, van der Velden WJFM, Feuth T, Kox M, Pickkers P, van de Veerdonk FL, Blijlevens NMA, Br\u00fcggemann RJM. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br. J. Clin. Pharmacol.<\/i>, 84<\/b>, 1980\u20131988 (2018).","DOI":"10.1111\/bcp.13627"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Vanstraelen K, Wauters J, De Loor H, Vercammen I, Annaert P, Lagrou K, Spriet I. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis. J. Pharm. Sci.<\/i>, 103<\/b>, 2565\u20132570 (2014).","DOI":"10.1002\/jps.24064"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Yuan ZQY, Qiao C, Yang ZC, Yu L, Sun LN, Qian Y, Zhang XH, Meng L, Zhang XY, Wang YQ. The impact of plasma protein binding characteristics and unbound concentration of voriconazole on its adverse drug reactions. Front. Pharmacol.<\/i>, 11<\/b>, 505 (2020).","DOI":"10.3389\/fphar.2020.00505"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Di L. An update on the importance of plasma protein binding in drug discovery and development. Expert Opin. Drug Discov.<\/i>, 16<\/b>, 1453\u20131465 (2021).","DOI":"10.1080\/17460441.2021.1961741"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Ceciliani F, Lecchi C. The immune function of \u03b1<\/i>1<\/sub> acid glycoprotein. Curr. Protein Pept. Sci.<\/i>, 20<\/b>, 505\u2013524 (2019).","DOI":"10.2174\/1389203720666190405101138"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nivoix Y, Lev\u00eaque D, Herbrecht R, Koffel JC, Beretz L, Ubreaud-Sequier G. The enzymatic basis on drug\u2013drug interactions with systemic triazole antifungals. Clin. Pharmacokinet.<\/i>, 47<\/b>, 779\u2013792 (2008).","DOI":"10.2165\/0003088-200847120-00003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Qi F, Zhu L, Li N, Ge T, Xu G, Liao S. Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents<\/i>, 49<\/b>, 403\u2013409 (2017).","DOI":"10.1016\/j.ijantimicag.2016.11.025"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O\u2019Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, I\u00f1arrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol.<\/i>, 33<\/b>, 550\u2013558 (2015).","DOI":"10.1200\/JCO.2014.57.9151"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Gu P, Li Y. Development and validation of a stability-indicating HPLC method for determination of voriconazole and its related substances. J. Chromatogr. Sci.<\/i>, 47<\/b>, 594\u2013598 (2009).","DOI":"10.1093\/chromsci\/47.7.594"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Florent A, Gandia P, Seraissol P, Chatelut E, Houin G. Determination of plasma unbound fraction of voriconazole in patients treated with a prophylactic or a curative treatment. Ther. Drug Monit.<\/i>, 36<\/b>, 752\u2013758 (2014).","DOI":"10.1097\/FTD.0000000000000095"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Shimamura K, Wajima T, Yano Y. Pharmacokinetic prediction for intravenous \u03b2<\/i>-lactam antibiotics in pediatric patients. J. Pharm. Sci.<\/i>, 96<\/b>, 3125\u20133139 (2007).","DOI":"10.1002\/jps.20977"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic\/pharmacodynamic profile of voriconazole. Clin. Pharmacokinet.<\/i>, 45<\/b>, 649\u2013663 (2006).","DOI":"10.2165\/00003088-200645070-00002"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) van Wanrooy MJP, Span LFR, Rodgers MGG, van den Heuvel ER, Uges DRA, van der Werf TS, Kosterink JGW, Alffenaar JWC. Inflammation is associated with voriconazole trough concentrations. Antimicrob. Agents Chemother.<\/i>, 58<\/b>, 7098\u20137101 (2014).","DOI":"10.1128\/AAC.03820-14"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Aiuchi N, Nakagawa J, Sakuraba H, Takahata T, Kamata K, Saito N, Ueno K, Ishiyama M, Yamagata K, Kayaba H, Niioka T. Impact of polymorphisms of pharmacokinetics-related genes and the inflammatory response on the metabolism of voriconazole. Pharmacol. Res. Perspect.<\/i>, 10<\/b>, e00935 (2022).","DOI":"10.1002\/prp2.935"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Miyakawa-Tanaka K, Suzuki J, Hirasawa Y, Nakamura S, Takeda K, Narumoto O, Matsui H. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: a retrospective cohort study. J. Infect. Chemother.<\/i>, 29<\/b>, 683\u2013687 (2023).","DOI":"10.1016\/j.jiac.2023.03.013"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) van den Born DA, M\u00e4rtson AG, Veringa A, Punt NC, van der Werf TS, Alffenaar JWC, Sturkenboom MGG, Touw DJ. Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model. Int. J. Antimicrob. Agents<\/i>, 61<\/b>, 106750 (2023).","DOI":"10.1016\/j.ijantimicag.2023.106750"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Hao X, Li Y, Zhang Y, Bian J, Zhao J, Zhao Y, Hu L, Luo X, Yang C, Feng Y, Huang L. Individualized treatment with voriconazole in the Chinese population: inflammation level as a novel marker for dose optimization. Br. J. Clin. Pharmacol.<\/i>, 90<\/b>, 440\u2013451 (2024).","DOI":"10.1111\/bcp.15916"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Klomp SD, Veringa A, Alffenaar JWC, de Boer MGJ, Span LFR, Guchelaar HJ, Swen JJ. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clin. Transl. Sci.<\/i>, 17<\/b>, e13887 (2024).","DOI":"10.1111\/cts.13887"},{"key":"33","unstructured":"33) Hamada Y, Kawasumi N, Hirai J, Yamagishi Y, Mikamo H. Evaluation of voriconazole oral dosage in Japan. Jpn. J. Antibiot.<\/i>, 67<\/b>, 279\u2013284 (2014)."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Dote S, Sawai M, Nozaki A, Naruhashi K, Kobayashi Y, Nakanishi H. A retrospective analysis of patient-specific factors on voriconazole clearance. J. Pharm. Health Care Sci.<\/i>, 2<\/b>, 10 (2016).","DOI":"10.1186\/s40780-016-0044-9"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Liang Z, Yu M, Liu Z, Liu F, Jia C, Xiong L, Dai Q, Qin S, Cheng L, Sun F. Inflammation affects liver function and the metabolism of voriconazole to voriconazole-N<\/i>-oxide in adult and elderly patients. Front. Pharmacol.<\/i>, 13<\/b>, 835871 (2022).","DOI":"10.3389\/fphar.2022.835871"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, Smith DA, Walker DK, Wood N. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab. Dispos.<\/i>, 31<\/b>, 731\u2013741 (2003).","DOI":"10.1124\/dmd.31.6.731"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Vanstraelen K, Wauters J, Vercammen I, de Loor H, Maertens J, Lagrou K, Annaert P, Spriet I. Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients. Antimicrob. Agents Chemother.<\/i>, 58<\/b>, 6782\u20136789 (2014).","DOI":"10.1128\/AAC.03641-14"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.<\/i>, 1482<\/b>, 157\u2013171 (2000).","DOI":"10.1016\/S0167-4838(00)00153-9"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Baumann H, Firestone GL, Burgess TL, Gross KW, Yamamoto KR, Held WA. Dexamethasone regulation of \u03b1<\/i>1-acid glycoprotein and other acute phase reactants in rat liver and hepatoma cells. J. Biol. Chem.<\/i>, 258<\/b>, 563\u2013570 (1983).","DOI":"10.1016\/S0021-9258(18)33291-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Mafuru M, Wu S, He S, Lu X, Huang J, Jiang H. The influence of proinflammatory cytokines on voriconazole trough concentration in patients with different forms of hematologic disorders. J. Clin. Pharmacol.<\/i>, 59<\/b>, 1340\u20131350 (2019).","DOI":"10.1002\/jcph.1422"},{"key":"41","unstructured":"41) Shibata K, Okubo H, Ishibashi H, Tsuda-Kawamura K, Yanase T. Rat alpha 1-acid glycoprotein: uptake by inflammatory and tumor tissues. Br. J. Exp. Pathol.<\/i>, 59<\/b>, 601\u2013608 (1978)."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol. Immunol.<\/i>, 38<\/b>, 189\u2013197 (2001).","DOI":"10.1016\/S0161-5890(01)00042-6"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Routledge PA. The plasma protein binding of basic drugs. Br. J. Clin. Pharmacol.<\/i>, 22<\/b>, 499\u2013506 (1986).","DOI":"10.1111\/j.1365-2125.1986.tb02927.x"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Matsumoto K, Sukimoto K, Nishi K, Maruyama T, Suenaga A, Otagiri M. Characterization of ligand binding sites on the alpha1-acid glycoprotein in humans, bovines and dogs. Drug Metab. Pharmacokinet.<\/i>, 17<\/b>, 300\u2013306 (2002).","DOI":"10.2133\/dmpk.17.300"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D, Watanabe H, Suenaga A, Maruyama T, Otagiri M. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human \u03b1<\/i>1-acid glycoprotein. J. Pharm. Sci.<\/i>, 98<\/b>, 4316\u20134326 (2009).","DOI":"10.1002\/jps.21697"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Nishi K, Ono T, Nakamura T, Fukunaga N, Izumi M, Watanabe H, Suenaga A, Maruyama T, Yamagata Y, Curry S, Otagiri M. Structural insights into differences in drug-binding selectivity between two forms of human \u03b1<\/i>1-acid glycoprotein genetic variants, the A and F1*S forms. J. Biol. Chem.<\/i>, 286<\/b>, 14427\u201314434 (2011).","DOI":"10.1074\/jbc.M110.208926"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Morell AG, Gregoriadis G, Scheinberg IH, Hickman J, Ashwell G. The role of sialic acid in determining the survival of glycoproteins in the circulation. J. Biol. Chem.<\/i>, 246<\/b>, 1461\u20131467 (1971).","DOI":"10.1016\/S0021-9258(19)76994-4"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Ishibashi S, Hammer RE, Herz J. Asialoglycoprotein receptor deficiency in mice lacking the minor receptor subunit. J. Biol. Chem.<\/i>, 269<\/b>, 27803\u201327806 (1994).","DOI":"10.1016\/S0021-9258(18)46855-X"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Braun JR, Willnow TE, Ishibashi S, Ashwell G, Herz J. The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. J. Biol. Chem.<\/i>, 271<\/b>, 21160\u201321166 (1996).","DOI":"10.1074\/jbc.271.35.21160"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Matsumoto K, Nishi K, Kikuchi M, Watanabe H, Nakajou K, Komori H, Kadowaki D, Suenaga A, Maruyama T, Otagiri M. Receptor-mediated uptake of human \u03b1<\/i>1-acid glycoprotein into liver parenchymal cells in mice. Drug Metab. Pharmacokinet.<\/i>, 25<\/b>, 101\u2013107 (2010).","DOI":"10.2133\/dmpk.25.101"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Nishi K, Komori H, Kikuchi M, Uehara N, Fukunaga N, Matsumoto K, Watanabe H, Nakajou K, Misumi S, Suenaga A, Maruyama T, Otagiri M. Characterization of the hepatic cellular uptake of \u03b11-acid glycoprotein (AGP), part 1: a peptide moiety of human AGP is recognized by the hemoglobin \u03b2-chain on mouse liver parenchymal cells. J. Pharm. Sci.<\/i>, 101<\/b>, 1599\u20131606 (2012).","DOI":"10.1002\/jps.22804"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Komori H, Nishi K, Uehara N, Watanabe H, Shuto T, Suenaga A, Maruyama T, Otagiri M. Characterization of hepatic cellular uptake of \u03b11-acid glycoprotein (AGP), part 2: involvement of hemoglobin \u03b2-chain on plasma membranes in the uptake of human AGP by liver parenchymal cells. J. Pharm. Sci.<\/i>, 101<\/b>, 1607\u20131615 (2012).","DOI":"10.1002\/jps.23015"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Nishi K, Maruyama T, Halsall HB, Handa T, Otagiri M. Binding of alpha1-acid glycoprotein to membrane results in a unique structural change and ligand release. Biochemistry<\/i>, 43<\/b>, 10513\u201310519 (2004).","DOI":"10.1021\/bi0400204"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) McCurdy TR, Bhakta V, Eltringham-Smith LJ, Gataiance S, Fox-Robichaud AE, Sheffield WP. In vivo<\/i> clearance of alpha-1 acid glycoprotein is influenced by the extent of its N-linked glycosylation and by its interaction with the vessel wall. J. Biomed. Biotechnol.<\/i>, 2012<\/b>, 292730 (2012).","DOI":"10.1155\/2012\/292730"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b25-00057\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:33:58Z","timestamp":1748662438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/5\/48_b25-00057\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00057","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"article-number":"b25-00057"}}